|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Market Access in Latin America
FirstWord Publishing, Aug 2010, Pages: 58
With its top eight markets valued at more than $30 billion in 2009, Latin America represents shining hope for an industry in flux.
Strong, steady growth, resiliency in the face of global downturn, positive regulatory frameworks and a motivated public all translate into one of the world’s leading emerging markets.
Yet, with seven cultural groups, an estimated population of 568 million and every political philosophy from left to right, the region also poses significant barriers. In some countries, such as Columbia, Mexico and Chile, right-of-centre politics mean a favourable regulatory environment and government support. In Venezuela, Ecuador, Bolivia and Nicaragua, however, left-leaning administrations can pose challenges.
And while country members of the Mercosur and Andean groups have joined forces to combine regulations and approval processes, there have been delays along the way. Regulatory frameworks overall have improved as a result of free trade and intellectual property agreements. Yet many administrations—intentionally or not—have promoted the generic industry.
Navigating such a diverse, colourful and dynamic region requires local knowledge, expert insight and up-to-date reporting. Pharmaceutical Market Access in Latin America offers the roadmap the industry needs to tap into Latin America’s possibilities. The report, which features extensive interviews with industry and government leaders, explains the regulatory, legal and geo-political environment, country by country. The dossier offers up-to-date insights into the use of market access consultants, five case studies of major firms’ experiences and an in-depth breakdown of inter-governmental pharmaceutical agreements, by institution or country.
The report offers insights into:
- The regulatory, geo-political and economic environment of 10 Latin American regions
- The increasing use of market access consultants by major pharmaceutical firms
Key features
- A country-by-country breakdown of major players, newcomers, infrastructure and industry operations
- Five case studies of major pharmaceutical companies
- Charts on inter-governmental agreements, legal and national public policy environments
- Description of attempts to standardize regulations and policy approval processes
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Generics Threats and Opportunities: Mounting an Effective Defense Strategy
Pharma Market Insights: Latin America
Market Access Brazil: Unlocking Pharma Potential.
Mexico Pharmaceuticals and Healthcare Report Q1 2010
Prescription Drugs - Global Strategic Business Report
Pharmaceuticals - Global Outlook
Opportunities in Emerging Markets - Newly Industrialized Asia (South Korea, Singapore, Taiwan, and Hong Kong SAR)
The Pharmaceutical Market: Colombia
Anti-Infectives - Global Strategic Business Report
The 2011 Leading Pharmaceutical Companies Financial Analyses
|
|
|
|
